The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off
I-Mab Biopharma and ABL Bio, Inc set their sights on adding the bispecific antibody, TJ-CD4B, to the expanding armamentarium for patients with various types of advanced and metastatic solid cancers.
Dabrafenib Plus Trametinib Provides Benefit Across Glioma SubtypesApril 12th 2021
Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.
Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid TumorsApril 11th 2021
Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.
Biomarkers Could Be Key in Bringing CDK4/6 Inhibitors to Adjuvant HR+/HER2- Breast CancerApril 8th 2021
Conflicting results regarding the benefit of adjuvant CDK4/6 inhibition in early-stage hormone receptor–positive, HER2-negative breast cancer have prompted many questions regarding patient selection and treatment duration, which many hope will be answered with ongoing biomarker research.
FDA Approves New Cetuximab Dose in KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck CancerApril 7th 2021
The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
PARP Inhibitors Could Help Craft Better Personalized Medicine in Prostate CancerApril 7th 2021
Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.
Searching for Molecular Targets in Myeloid Malignancies and BeyondApril 6th 2021
Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.
TPX-0046 Showcases Early Clinical Activity in RET-Driven Advanced Solid TumorsApril 6th 2021
The RET inhibitor TPX-0046 demonstrated encouraging preliminary activity, which included objective responses, and an acceptable toxicity profile when used in patients with RET-driven advanced solid tumors.
FDA Grants Breakthrough Therapy Designation to Futibatinib for FGFR2+ Advanced CholangiocarcinomaApril 1st 2021
The FDA has granted a breakthrough therapy designation to the FGFR inhibitor futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors FGFR2 gene rearrangements, including fusions.
OncLive® Takes a Look Back at Most Listened Podcasts of 2020April 1st 2021
Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.
Gilteritinib Succeeds in Chinese Confirmatory Trial for FLT3-Mutated AMLMarch 30th 2021
Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.
Frontline Osimertinib Showcases Real-World Safety, Efficacy in EGFR+ Advanced NSCLCMarch 27th 2021
Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.
Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLCMarch 25th 2021
Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.
FASN Inhibitor AZ12756122 Reduces Resistance Properties in EGFR TKI–Resistant, EGFR-Mutant NSCLC ModelsMarch 25th 2021
The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.
Ki-67 Is Poised to Advance as a Biomarker in Early-Stage Breast CancerMarch 24th 2021
Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.
Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLCMarch 15th 2021
Janakiraman Subramanian, MD, discusses the depth and durability of responses that have been reported with selpercatinib and pralsetinib, as well as ongoing research focused on improving outcomes and overcoming resistance mechanisms in RET fusion–positive NSCLC.